Dr. Weiguo Su has been the Chief Executive Officer of HUTCHMED since March 2022. He has been Chief Scientific Officer of the company since 2012. Dr. Su has headed all drug discovery and research since he joined HUTCHMED, including master-minding the scientific strategy of the company, being a key leader of the Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in the company’s pipeline. Prior to joining HUTCHMED in 2005, Dr. Su worked with the U.S. research and development department of Pfizer, Inc.
In 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai and completed a PhD and Post-Doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
In 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai and completed a PhD and Post-Doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Speaking In
11:00 AM - 12:00 PM
Wednesday, June 7